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This research employs text and data mining methods to gain valuable
knowledge for human drugs. Specifically, computational methods are
developed for three topics, namely drug-side-effect prediction, drug-target
identification, and drug-drug-interaction detection. The key innovations of
the proposed methods lie in the feature space construction using medical
domain knowledge, generation of reliable negative samples, and successful
application of machine learning algorithms.
The drug-side-effect prediction problems are studied in Chapters 3-5.
Side-effects are secondary phenotypic responses of human organisms to drug
treatments. Side-effect prediction is an important topic for drugs especially in
post-marketing surveillance because they cause significant fatality and severe
morbidity. To overcome the limitations of existing computational methods
such as lack of proper drug representation and reliable negative samples, this
thesis presents three novel methods.
The first method is to predict side-effects for single drug medication
as described in Chapter 3. A comprehensive drug similarity framework is
developed by integrating several types of similarities measured by representative
features of drugs first. Then reliable negative samples are generated through
analyzing the comprehensive drug similarities. Trained with generated
reliable negatives, the prediction performance of four classical classifiers
are improved significantly, outperforming those state-of-the-art methods.
Chapter 4 describes the method proposed to predict side-effects for combined
medication of multi-drugs. A scoring method on a drug-disease-gene
xxi
Abstract
tripartite network is developed to prioritize interacting drugs, paving a
way to generate credible negative samples for side-effect prediction of
combined medication. It creatively characterized a drug with its chemical
structures, target proteins, substituents, and enriched pathways. The drug-
drug pairs are represented as novel feature vectors to train binary classifiers
for prediction. This novel representation and the inferred negative samples
contribute to the superior performance of the proposed method in drug-
drug-side-effect association prediction. Chapter 5 introduces the last method
for detecting adverse drug reactions (ADRs, i.e., side-effects) from medical
forums. It filters the cause-result relationship between drugs and ADRs using
a self-built dictionary and detects drug-ADRs associations by information
entropy. Compared with conventional co-occurrence based methods, the
proposed method captures both high-frequency and low-frequency ADRs
simultaneously. Besides, it returns drug-related ADRs only owing to the
self-built relation dictionary.
Drug-target identification plays a crucial role in drug discovery. Existing
computational methods have achieved remarkable prediction accuracy, however,
usually obtain poor prediction efficiency due to computational problems.
Chapter 6 presents a method to improve the prediction efficiency using an
advanced technique named anchor graph hashing (AGH). AGH embeds data
into low-dimensional Hamming space while maintaining the neighbourship.
It turns the drug-target identification problem into a binary classification
task where inputs are AGH-embedded vectors of drug-target pairs, and
labels are judgments of their associations. Ensemble learning with random
forest and XGBoost is employed to learn a good decision boundary. The
proposed method is demonstrated to be the most efficient method and
achieves comparable prediction accuracy with the best literature method.
Chapter 7 introduces a novel positive-unlabeled learning method named
DDI-PULearn for large-scale detection of drug-drug interactions (DDIs).
DDI-PULearn first generates seeds of reliable negatives via OCSVM (one-
class support vector machine) under a high-recall constraint and via the
xxii
Abstract
cosine-similarity based KNN (k-nearest neighbors) as well. Then trained
with all the labeled positives (i.e., validated DDIs) and the generated seed
negatives, DDI-PULearn employs an iterative SVM to identify the set of
entire reliable negatives from the unlabeled samples. The identified negatives
and validated positives are represented as vectors using the bit-wise similarity
of corresponding drug pairs to train random forest for prediction. Its excellent
performance is confirmed by comparing with two baseline methods and five
state-of-the-art methods.
xxiii

